Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The standard treatment for rectal cancer is to receive the chemotherapeutic drug
5-fluorouracil (5-FU) with radiation therapy before having surgery to remove the rectal
cancer. This is known as neoadjuvant chemoradiotherapy. The purpose of this research study is
to determine if Cetuximab improves the benefits of neoadjuvant chemoradiotherapy when given
with 5-FU and radiation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Bristol-Myers Squibb Massachusetts General Hospital